PMID: 2859203Jan 1, 1985Paper

Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol

European Journal of Clinical Pharmacology
P DayerJ Rosenthaler


Ten healthy subjects whose genetic oxidative phenotype had been determined (6 extensive and 4 poor metabolizers of the debrisoquine-sparteine type of polymorphism) received single oral doses of 3 beta-blockers: atenolol, bopindolol and metoprolol. The plasma concentrations and the extent of the decrease in exercise-induced tachycardia were determined. The oxidative polymorphism was only significant for substances that had a high hepatic first pass metabolism, such as metoprolol. The metabolic pathway under genetic control was highly stereoselective. This observation must be taken into account when assessing the relation between the plasma concentration and effect of these drugs, which are often administered as racemic mixtures.


Jun 1, 1975·The Journal of Pharmacy and Pharmacology·B Scales, P B Copsey
May 1, 1980·European Journal of Clinical Pharmacology·D B BarnettS R Nahorski
Jan 1, 1982·European Journal of Drug Metabolism and Pharmacokinetics·P DayerJ Fabre
May 1, 1982·British Journal of Clinical Pharmacology·P DayerJ Fabre
Aug 1, 1982·British Journal of Clinical Pharmacology·M S LennardJ Trevethick
Jan 1, 1982·European Journal of Clinical Pharmacology·R J FrancisJ Larman


Jan 1, 1989·European Journal of Clinical Pharmacology·M HildebrandA Reichenberger
Jan 1, 1986·European Journal of Clinical Pharmacology·T LeemannU A Meyer
Nov 15, 1985·Klinische Wochenschrift·C ZekornM Eichelbaum
Jun 12, 2008·European Journal of Clinical Pharmacology·Angela SeeringerJulia Kirchheiner
Jan 1, 1989·Pharmacology & Therapeutics·M S Lennard
Jan 1, 1990·Pharmacology & Therapeutics·T H Pringle, J G Riddell
Oct 13, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Jan 7, 2014·Analytical and Bioanalytical Chemistry·Megan M McCallumLeggy A Arnold
Jan 1, 1987·European Journal of Clinical Pharmacology·L J SchaafD G Perrier
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Nov 18, 2005·Journal of Clinical Pharmacology·Paula Macedo CerqueiraVera Lucia Lanchote
Apr 20, 2010·Journal of Clinical Pharmacology·Stephen M StoutBarry E Bleske
Dec 3, 2014·The Journal of Allergy and Clinical Immunology·Maria NassiriMargitta Worm
Oct 1, 1990·Biochemical Pharmacology·S S MurthyM S Lennard

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.